Update

Last year's "triple-demic" marked the beginning of a confluence of respiratory infections that began to fill hospitals, which is why Biden has awarded companies $1 billion to develop COVID vaccines that provide longer protection.

Because of aggressive marketing by firms encouraging small businesses to claim the pandemic-era tax break, the feds are worried about fraud, however, tax experts disagree on whether or not the 180-day extension is necessary.

Many states have passed laws that allow hospital systems to merge into monopolies, making them difficult to control and causing a decrease in care – and public records suggest that's exactly what happened at Ballad Health.

The House and Senate have until Saturday, Sept. 30 to pass a spending deal, which means congressional gridlock is poised to at least temporarily shut down certain health programs, like the drug price negotiations set to begin Oct. 1.

Thousands of patients with autoimmune diseases rely on Humira, at a list price of $6,600 a month, and could benefit from low-cost biosimilars that could save the health care system $9 billion a year, but will PBMs follow suit?

The Federal Trade Commission, which is reviewing the business practices of the largest PBMs – including CVS, Express Scripts, OptumRx, and Humana – grilled two nominees on the subject at their confirmation hearing.

Three influential medical organizations say the reimbursement proposal reductions for 2024 - a 3.3% cut in the conversion factor, the formula used to determine Medicare's physician payments - would hurt providers.

The nation's leading lobbying group for seniors filed an amicus brief on Monday in Washington, D.C., urging a federal court to dismiss a lawsuit filed by Merck to challenge Medicare's Drug Price Negotiation Program.